Limitations
This study has limitations. The primary limitation is the low number of patients categorized as high risk. Even though our analyses indicated no differences in treatment effect by risk status, there may not have been enough individuals in the high-risk group (21 [7.2%]) to confidently make this determination. The original trial in the United Kingdom had a 4-fold higher rate of high-risk patients (28%).